DE602005021681D1 - Stibogluconate-natrium und il-2 zur krebsbehandlung - Google Patents

Stibogluconate-natrium und il-2 zur krebsbehandlung

Info

Publication number
DE602005021681D1
DE602005021681D1 DE602005021681T DE602005021681T DE602005021681D1 DE 602005021681 D1 DE602005021681 D1 DE 602005021681D1 DE 602005021681 T DE602005021681 T DE 602005021681T DE 602005021681 T DE602005021681 T DE 602005021681T DE 602005021681 D1 DE602005021681 D1 DE 602005021681D1
Authority
DE
Germany
Prior art keywords
cancer treatment
stibogluconate sodium
stibogluconate
sodium
ptpase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005021681T
Other languages
English (en)
Inventor
Taolin Yi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of DE602005021681D1 publication Critical patent/DE602005021681D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602005021681T 2004-11-11 2005-11-10 Stibogluconate-natrium und il-2 zur krebsbehandlung Active DE602005021681D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/987,217 US20050215629A1 (en) 2001-09-07 2004-11-11 PTPase inhibitors and methods of using the same
PCT/US2005/040825 WO2006053162A1 (en) 2004-11-11 2005-11-10 Ptpase inhibitors and t-cell activators for treating cancer

Publications (1)

Publication Number Publication Date
DE602005021681D1 true DE602005021681D1 (de) 2010-07-15

Family

ID=35945240

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005021681T Active DE602005021681D1 (de) 2004-11-11 2005-11-10 Stibogluconate-natrium und il-2 zur krebsbehandlung

Country Status (9)

Country Link
US (1) US20050215629A1 (de)
EP (1) EP1817057B1 (de)
JP (1) JP2008519845A (de)
AT (1) ATE469659T1 (de)
AU (1) AU2005304422A1 (de)
CA (1) CA2587336A1 (de)
DE (1) DE602005021681D1 (de)
HK (1) HK1107778A1 (de)
WO (1) WO2006053162A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215629A1 (en) * 2001-09-07 2005-09-29 Taolin Yi PTPase inhibitors and methods of using the same
TW200803835A (en) * 2006-01-11 2008-01-16 Cleveland Clinic Foundation Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
WO2007149382A2 (en) * 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in treating hepatitis
US20080226596A1 (en) * 2006-06-19 2008-09-18 Taolin Yi Therapeutic compositions and methods useful in treating hepatitis
WO2007149381A2 (en) * 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Compositions comprising a ptp-ase inhibitor and use thereof in treating cancer
GB0916124D0 (en) 2009-09-15 2009-10-28 Univ Cardiff Method and kit for the classification and prognosis of wounds
GB201021182D0 (en) 2010-12-14 2011-01-26 Univ Cardiff Methdo and kit for the classification and prognosis of chronic wounds
GB201103898D0 (en) 2011-03-08 2011-04-20 Univ Cardiff Molecular targets for healing or treating wounds
CN111803475B (zh) * 2019-04-10 2023-06-23 中美（河南）荷美尔肿瘤研究院 喷他脒在制备抑制pd1和pd-l1蛋白之间相互作用药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63139134A (ja) * 1986-12-02 1988-06-10 Kyowa Hakko Kogyo Co Ltd Ｔ細胞活性化剤
ATE77947T1 (de) * 1987-04-09 1992-07-15 Fisons Plc Pentamidin enthaltende pharmazeutische zusammensetzungen.
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
US5798339A (en) * 1990-12-17 1998-08-25 University Of Manitoba Treatment method for cancer
US6177460B1 (en) * 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US5798374A (en) * 1995-06-07 1998-08-25 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith
US6388076B1 (en) * 1995-06-19 2002-05-14 Ontogen Corporation Protein tyrosine phosphatase-inhibiting compounds
US6207145B1 (en) * 1997-05-09 2001-03-27 Pharma Pacific Pty Ltd. Therapeutic applications of high dose interferon
US6020179A (en) * 1996-10-03 2000-02-01 Incyte Pharmaceuticals, Inc. Nucleic acids encoding human tyrosine phosphatases
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
IN183330B (de) * 1998-03-23 1999-11-20 Dalmia Ct For Biotechnology
US6258582B1 (en) * 1998-09-30 2001-07-10 Millennium Pharmaceuticals, Inc. CSAPTP nucleic acid molecules and uses therefor
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
AU2002312170B8 (en) * 2001-05-31 2008-07-31 The Cleveland Clinic Foundation PTPase inhibitors and method of using same
EP1572070A4 (de) * 2001-09-07 2009-11-04 Cleveland Clinic Foundation Therapeutische zusammensetzungen und verfahren zur modulierung von protein-tyrosin-phosphatasen
US20030161893A1 (en) * 2001-09-07 2003-08-28 Taolin Yi PTPase inhibitors and methods of using the same
US20050215629A1 (en) * 2001-09-07 2005-09-29 Taolin Yi PTPase inhibitors and methods of using the same
WO2003063788A2 (en) * 2002-01-30 2003-08-07 The Cleveland Clinic Foundation PTPase INHIBITORS AND METHODS OF USING THE SAME

Also Published As

Publication number Publication date
ATE469659T1 (de) 2010-06-15
CA2587336A1 (en) 2006-05-18
WO2006053162A1 (en) 2006-05-18
HK1107778A1 (en) 2008-04-18
EP1817057B1 (de) 2010-06-02
US20050215629A1 (en) 2005-09-29
AU2005304422A1 (en) 2006-05-18
JP2008519845A (ja) 2008-06-12
EP1817057A1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
TW200612918A (en) Lonidamine analogs
ATE481092T1 (de) Verfahren und zusammensetzungen zur apoptoseinduktion in krebszellen
TW200501960A (en) Synergistic kits and compositions for treating cancer
MXPA05005398A (es) Meta para terapia de deterioro cognitivo.
MXPA05013822A (es) Pirrolodihidroisoquinolinas utiles en el tratamiento del cancer.
DK1261367T3 (da) Anvendelse af interleukin-6-antagonister til behandling af östrogenafhængige tumorer
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
DK1660507T3 (da) Proteasominibitorer og metoder til anvendelse heraf
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
DE60238058D1 (de) Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
EA200600424A1 (ru) Применение полипептидов семейства купредоксинов при лечении рака
WO2003103581A3 (en) COMPOSITIONS AND METHODS FOR LIVER GROWTH AND PROTECTION
MY141851A (en) Human monoclonal antibodies against human il-4
TW200508233A (en) Chk-1 inhibitors
SI1546182T1 (sl) Sestavki in postopki za diagnozo in zdravljenje tumorja
MY162518A (en) Proteasome inhibitors and methods of using the same
SG147469A1 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
AU316238S (en) Lawning applicator for microbiological cultures
ATE431742T1 (de) Modifizierte zytokine für krebs therapie
ATE489947T1 (de) Axomadol zur schmerzbehandlung bei arthrose
MXPA04007007A (es) Uso de inhibidores del intercambiador cloruro/bicarbonato dependiente del sodio para el tratamiento de enfermedades tromboticas e inflamatorias.
DE10344882A1 (de) Neue Makrocyclen zur Behandlung von Krebserkrankungen